Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The use of TRESIBA for this indication is supported by evidence from an adequate and well-controlled trial and a pharmacokinetic study (trials included pediatric patients 1 year of age and older with type 1 diabetes mellitus) [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)]
V vy L-Carnitine vi chc nng chuyn ha acid bo thnh nng lng l cht v cng cn thit tim c th hot ng bnh thng
Low-quality evidence from another trial that compared the effect of ALCAR (1.5 g/day) with that of methylcobalamin (1.5 mg/day) for 24 weeks suggested no difference between treatments regarding the extent of functional disability (using the Neuropathy Disability Scale) or measures of symptom quality and severity (using the Neuropathy Symptom Scale) (89)
Most people tolerate both medication types well after initial adjustment
US$ 28.35
US$ 28.40
US$ 29.78
US$ 27.75
US$ 24.97
US$ 22.90
US$ 20.00
